| 1 (37) | Sanofi * | MUL |  |
| 2 (38) | Sanofi, United States | USA | |
| 3 (41) | Boehringer Ingelheim GmbH Germany | DEU | |
| 4 (55) | Samsung Corp * | MUL | |
| 5 (61) | GlaxoSmithKline * | MUL | |
| 6 (79) | Boehringer Ingelheim * | MUL | |
| 7 (92) | GlaxoSmithKline, United States | USA | |
| 8 (103) | Pfizer Inc, United States | USA | |
| 9 (107) | IBM United States | USA | |
| 10 (115) | Merck * | MUL | |
| 11 (137) | Pfizer * | MUL | |
| 12 (161) | GlaxoSmithKline, Belgium | BEL | |
| 13 (181) | Merck & Co Inc, United States | USA | |
| 14 (213) | IBM Research * | MUL | |
| 15 (236) | RTI Health Solutions | USA | |
| 16 (240) | AstraZeneca * | MUL | |
| 17 (321) | Novartis * | MUL | |
| 18 (360) | Bayer * | MUL | |
| 19 (388) | BASF Group * | MUL | |
| 20 (399) | Novartis Pharmaceuticals, United States | USA | |
| 21 (439) | F Hoffmann-La Roche * | MUL | |
| 22 (474) | Aramco * | MUL | |
| 22 (474) | Saudi Arabian Oil Company | SAU | |
| 24 (559) | Manipal Global Education Group * | MUL | |
| 25 (576) | GlaxoSmithKline, United Kingdom | GBR | |
| 26 (587) | Johnson & Johnson * | MUL | |
| 27 (592) | Hoffmann-La Roche Ltd, United States | USA | |
| 28 (598) | AstraZeneca, Sweden | SWE | |
| 29 (604) | Novo Nordisk * | MUL | |
| 30 (614) | Takeda Pharmaceuticals International Inc * | MUL | |
| 31 (615) | Novo Nordisk A/S | DNK | |
| 32 (622) | SINTEF Group | NOR | |
| 33 (637) | Genentech Inc | USA | |
| 33 (637) | AstraZeneca, United Kingdom | GBR | |
| 35 (649) | AstraZeneca, United States | USA | |
| 36 (654) | Eli Lilly * | MUL | |
| 37 (656) | IMEC International | BEL | |
| 38 (662) | Novartis, Switzerland | CHE | |
| 39 (671) | Janssen | MUL | |
| 40 (694) | Eli Lilly and Company, United States | USA | |
| 41 (702) | Amgen * | MUL | |
| 42 (712) | Amgen, USA | USA | |
| 43 (737) | Estacio Participacoes SA * | BRA | |
| 44 (742) | Gilead Sciences * | MUL | |
| 44 (742) | Gilead Sciences Inc, United States | USA | |
| 46 (746) | Janssen Biotech Inc | USA | |
|
